Elevance Health price target raised to $450 from $400 at Cantor Fitzgerald
Cantor Fitzgerald analyst Sarah James raised the firm's price target on Elevance Health to $450 from $400 and keeps an Overweight rating on the shares. Cantor prefers payors over providers heading into Q2 earnings, supported by management discussions, proprietary checks, and investor conversations, the analyst tells investors in a research note. Payors appear better positioned with continued strength in government insurance lines and VBC opportunities, while provider commentary may struggle to meet elevated expectations, limiting upside despite potential guidance increases, the firm says.
Cantor Fitzgerald analyst Sarah James raised the firm's price target on Elevance Health to $450 from $400 and keeps an Overweight rating on the shares.
Cantor prefers payors over providers heading into Q2 earnings, supported by management discussions, proprietary checks, and investor conversations, the analyst tells investors in a research note.
Payors appear better positioned with continued strength in government insurance lines and VBC opportunities, while provider commentary may struggle to meet elevated expectations, limiting upside despite potential guidance increases, the firm says.